KRAS Mutations An Old Oncogene Becomes a New Predictive Biomarker

被引：43

作者：

Riely, Gregory J. ^{[1
]}

Ladanyi, Marc ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Pathol & Human Oncol & Pathogenesis, New York, NY 10065 USA

来源：

JOURNAL OF MOLECULAR DIAGNOSTICS | 2008年 / 10卷 / 06期

关键词：

D O I：

10.2353/jmoldx.2008.080105

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

引用

页码：493 / 495

页数：3

共 28 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2]

[Anonymous], J CLIN ONCOL S

[3] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[4] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[7] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[8] Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation [J].

Han, SW ;

Kim, TY ;

Jeon, YK ;

Hwang, PG ;

Im, SA ;

Lee, KH ;

Kim, JH ;

Kim, DW ;

Heo, DS ;

Kim, NK ;

Chung, DH ;

Bang, YJ .

CLINICAL CANCER RESEARCH, 2006, 12 (08) :2538-2544

[9] Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib [J].

Hirsch, F. R. ;

Varella-Garcia, M. ;

Cappuzzo, F. ;

McCoy, J. ;

Bemis, L. ;

Xavier, A. C. ;

Dziadziuszko, R. ;

Gumerlock, P. ;

Chansky, K. ;

West, H. ;

Gazdar, A. F. ;

Crino, L. ;

Gandara, D. R. ;

Franklin, W. A. ;

Bunn, P. A., Jr. .

ANNALS OF ONCOLOGY, 2007, 18 (04) :752-760

[10] Epidermal growth factor receptor inhibitors in lung cancer: Smaller or larger molecules, selected or unselected populations? [J].

Hirsch, FR ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9044-9047

← 1 2 3 →